Cardiovascular Diseases
Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact
Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones
Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio
Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease
CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing
CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader
Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases
Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial
lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy
Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal
Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community
Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL
FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease
Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist
RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment
RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.